GeneDx Holdings Corp. (WGS)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $1.57B
Last updated: Nov 17, 2026 at 11:05 AM ET
GeneDx Holdings Corp. (WGS) P/E Ratio & Valuation History
GeneDx Holdings (WGS) trades at 340.1x trailing earnings and 3.3x sales. Its P/S of 3.3x is below its 5-year median of 3.8x. Its forward P/E is 38.8x.
Current Multiples
Its forward P/E is below its trailing P/E, which implies earnings per share about 776.5% higher over the next year.
| Multiple | Value |
|---|---|
| P/E (trailing) | 340.1x |
| Forward P/E | 38.8x |
| Price to sales | 3.3x |
| Price to book | 6.2x |
| PEG | N/A |
| FCF yield | -6.6% |
Historical Medians
| Multiple | Current | 5-year median | 10-year median |
|---|---|---|---|
| P/S | 3.3x | 3.8x | N/A |
| P/B | 6.2x | 2.8x | N/A |
Valuation History
Over the 4 of the 6 year ends shown that have a P/S, its P/S ranged from 0.3x in 2023 to 8.5x in 2025. 2025 was the highest of those years.
| Year end | Price | P/E | P/S | P/B |
|---|---|---|---|---|
| 2025 | $130.06 | 92.9x | 8.5x | 11.3x |
| 2024 | $76.86 | 313.3x | 6.7x | 8.5x |
| 2023 | $2.75 | N/A | 0.3x | 0.3x |
| 2022 | $8.71 | N/A | 0.4x | 0.4x |
| 2021 | $147.19 | N/A | N/A | 2.8x |
| 2020 | $364.36 | N/A | N/A | N/A |
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About WGS
What is WGS's forward P/E ratio?
GeneDx Holdings has a forward P/E ratio of 38.8x.
Is WGS stock overvalued?
GNG's valuation label for WGS is Overvalued.
What is WGS's price to sales ratio?
GeneDx Holdings has a price to sales ratio of 3.3x.
WGS pages: Overview, Earnings, Forecast, Financials, Valuation